Travere Therapeutics Inc

TVTX remains in a Stage 2 advancing phase with strong medium- and long-term uptrends. Active Higher Highs & Higher Lows and Lockout Rally patterns confirm demand-dominated continuation. Price is pulling back into the rising 9-EMA and 20-EMA zone, offering a favorable entry for continuation participation. Despite extreme overbought readings, Lockout Rally dynamics support further extension. Key risks include a breach of the EMA support zone and overhead resistance near recent highs.

• ↑Q1 revenue $124.5M, up 88% YoY driven by Filspari adoption.
• ↑Filspari sales of $105.2M with 993 new patient start forms.
• ↓Net loss $37.1M in Q1 raises operational sustainability concerns.